Mitochondrially targeted tamoxifen in patients with metastatic solid tumours: an open-label, phase I/Ib single-centre trialResearch in context

Summary: Background: Mitochondria present an emerging target for cancer treatment. We have investigated the effect of mitochondrially targeted tamoxifen (MitoTam), a first-in-class anti-cancer agent, in patients with solid metastatic tumours. Methods: MitoTam was tested in an open-label, single-cen...

Descripció completa

Dades bibliogràfiques

Autors principals:	Zuzana Bielcikova, Jan Stursa, Ludmila Krizova, Lanfeng Dong, Jan Spacek, Stanislav Hlousek, Michal Vocka, Katerina Rohlenova, Olga Bartosova, Vladimir Cerny, Tomas Padrta, Michal Pesta, Pavel Michalek, Sona Stemberkova Hubackova, Katarina Kolostova, Eliska Pospisilova, Vladimir Bobek, Peter Klezl, Renata Zobalova, Berwini Endaya, Jakub Rohlena, Lubos Petruzelka, Lukas Werner, Jiri Neuzil
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2023-03-01
Col·lecció:	EClinicalMedicine
Matèries:	Phase I/Ib clinical trial Cancer Mitochondrially targeted tamoxifen Renal cell carcinoma
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2589537023000500
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!